RhumbLine Advisers’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-20,882
Closed -$103K 2885
2016
Q4
$103K Buy
20,882
+1,313
+7% +$6.72K ﹤0.01% 2793
2016
Q3
$97K Hold
19,569
﹤0.01% 2813
2016
Q2
$100K Buy
19,569
+95
+0.5% +$512 ﹤0.01% 2916
2016
Q1
$111K Buy
19,474
+290
+2% +$2.02K ﹤0.01% 2876
2015
Q4
$199K Sell
19,184
-505
-3% -$6.85K ﹤0.01% 2802
2015
Q3
$364K Buy
19,689
+635
+3% +$12.3K ﹤0.01% 2431
2015
Q2
$371K Sell
19,054
-1,180
-6% -$20.9K ﹤0.01% 2523
2015
Q1
$356K Buy
20,234
+2,100
+12% +$35.3K ﹤0.01% 2518
2014
Q4
$290K Buy
18,134
+575
+3% +$7.7K ﹤0.01% 2608
2014
Q3
$221K Buy
17,559
+200
+1% +$2.85K ﹤0.01% 2694
2014
Q2
$271K Buy
17,359
+1,290
+8% +$19K ﹤0.01% 2661
2014
Q1
$211K Sell
16,069
-800
-5% -$12.5K ﹤0.01% 2747
2013
Q4
$271K Hold
16,869
﹤0.01% 2651
2013
Q3
$281K Sell
16,869
-171
-1% -$2.53K ﹤0.01% 2579
2013
Q2
$172K Buy
+17,040
New +$179K ﹤0.01% 3061

Other funds holding OSIR

RhumbLine Advisers's OSIR Position: Q1 2017 in Review

RhumbLine Advisers sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q1 2017, closing a stake of 20,882 shares — an estimated $103K sold.

RhumbLine Advisers first reported a position in OSIR in Q2 2013 and held it in 15 quarters. The position peaked at $371K in Q2 2015. 11 funds tracked by Wall St. Rank hold OSIR as of Q1 2017.

  • RhumbLine Advisers reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • RhumbLine Advisers sold 20,882 Osiris Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $103K.
  • RhumbLine Advisers first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 15 quarters.
  • RhumbLine Advisers's Osiris Therapeutics, Inc. Common Stock position peaked at $371K in Q2 2015.
  • 11 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q1 2017.

Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.